Navigation Links
Amgen Announces 2011 Fourth Quarter Dividend
Date:10/13/2011

to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to
'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen to Present at the UBS Global Life Sciences Conference
2. Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits
3. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures(TM) Educational Campaign
4. Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign
5. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
6. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
7. Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
8. Amgen Statement on CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
9. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
10. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
11. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
(Date:6/30/2015)... R-Japan Co.,Ltd. obtained the license of cell processing ... from the Ministry of Health, Labour and Welfare Kinki Bureau ... The fact that R- Japan received ... Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 ... stem cell manufacturing service to medical institutions. As of November ...
(Date:6/30/2015)...  NASA astronaut Kjell Lindgren , who is making ... mission to the International Space Station , will be ... EDT Tuesday, July 7. Lindgren will participate from ... Russia . The interviews will be preceded at 7:30 ... training. To schedule an interview, media must contact ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... that does not sacrifice selectivity to achieve faster flow rates in comparison to ... pores with significant open space to allow easy liquid flow while trapping particulates ...
Breaking Biology Technology:Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2
... Highlight Applications in Inventory Management, Disposables ... WESTMINSTER, Colo., Dec. 11 , WHAT: This presentation identifies ... medical devices and supplies and explains how embedded RFID ... a way that enhances safety ...
... - TB-402 Shows Clear Promise as a Stable ... ThromboGenics NV (Euronext Brussels:THR), a biotechnology company,focused on ... of the,first Phase I trial of TB-402 were ... (ASH) 49th Annual Meeting in Atlanta,Georgia, USA. TB-402 ...
... ALACHUA, Fla., Dec. 10 Tutogen Medical, Inc.,(Amex: TTG ... human (allograft) and animal (xenograft) tissue, today announced,financial results for ... Summary of 2007 Highlights for the fiscal year ... 42%; -- Sales of dental products increased 38% ...
Cached Biology Technology:SkyeTek to Present Webinar on Transforming the Management of Medical Devices & Supplies with Embedded RFID 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
(Date:6/15/2015)... 16, 2015 According to a ... Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, ... published by MarketsandMarkets, The Natural Language Processing Market is ... of 18.4% for the forecast period 2015-2020. ... F igures spread   through 155 P ...
(Date:6/10/2015)... , June 10, 2015 ... Sensor Market by Technology (Ultrasound, TOF, Structured Light, ... Electronics, Entertainment, Automotive) and by Geography - Trends ... MarketsandMarkets, the market is expected to reach $3,319.71 ... 25.51% between 2015 and 2020. Browse ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 53D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... 13, 2013) When a research team from Denmark ... cells (ASCs) versus bone marrow-derived stem cells (BMSCs) obtained ... coronary disease to regeneratively treat myocardial infarction in a ... cardiac function in the test rats while neither stem ...
... FEBRUARY 13, 2013 The experimental drug selumetinib may allow ... radioiodine (RAI), the most effective therapy for the disease, according ... Published in the February 14 issue of the New ... for patients with a disease that can have a poor ...
... neglected part of the obesity epidemic is that it ... pregnancy. Their offspring also tend to have higher birth ... risk of obesity and chronic diseases later in life. ... during pregnancy that may influence child obesity remain uncertain. ...
Cached Biology News:Stem cell source an important factor, impacting ability to treat myocardial infarction 2Drug shown to reverse radioiodine resistance in some advanced thyroid cancers 2Preventing obesity transmission during pregnancy 2
... ViaSure Kit is used in conjunction with the ... cells automatically. The ViaSure Staining Reagent uses ... Acridine Orange and Ethidium Bromide to identify live ... while the EasyCount Slide 6 Multi-well Slide ...
... Kit provides a powerful yet simple technology ... acids. The kit provides the heterobifunctional linkers ... quantifying conjugation efficiencies. It enables conjugation of ... other tags with a variety of proteins. ...
... Pierce offers maleimide activated carrier ... hapten-carrier conjugates. Imject Maleimide Activated Carrier ... have been preactivated with a heterobifunctional ... a stable, sulfhydryl-reactive carrier protein. ...
...
Biology Products: